Get the Daily Brief
Latest Biotech News
Innovations in oncology therapeutics and clinical advances spotlighted at ASTRO 2025
Leading cancer centers revealed pivotal advances for radiation oncology at the 2025 ASTRO meeting. MD Anderson showcased data establishing stereotactic body radiation therapy (SBRT) matching...
Standardized organoid center launched by NIH to replace animal testing in drug development
The US National Institutes of Health announced the Standardized Organoid Modeling Center with $87 million in funding over three years to establish reproducible, scalable organoid research...
Pan-cancer immunotherapy breakthrough targets glycans to kill tumors while sparing healthy tissue
University of California Irvine researchers developed glycan-dependent T cell recruiters (GlyTRs), a novel class of biologics that employ velcro-like sugar-binding technology to selectively engage...
Crucial genomic discoveries advance understanding and treatment of cancer and other diseases
Recent studies unveil significant genetic insights shaping diagnosis and therapy. UCLA uncovered a key protein, IGF2BP3, linking cancer metabolism and RNA regulation in leukemia, presenting new...
Biotech financing surges with nine-figure rounds fueling innovation and expansion
Major biotech firms MBX Biosciences and uniQure attracted substantial nine-figure fundraising rounds, reflecting sustained investor confidence in life sciences despite political and economic...
Crinetics Gains FDA Approval: Oral Acromegaly Drug Challenges Injectables
Crinetics Pharmaceuticals secured FDA approval for Palsonify (paltusotine), the first oral, once-daily first-line therapy for adults with acromegaly. This rare endocrine disorder results from...
Eli Lilly’s Oral SERD Inluriyo Approved for Advanced Breast Cancer
The FDA approved Eli Lilly’s oral selective estrogen receptor degrader (SERD), imlunestrant (marketed as Inluriyo), for treating adults with advanced or metastatic estrogen receptor-positive,...
Trump Administration Enforces 100% Tariffs on Imported Pharmaceuticals
President Trump announced a 100% tariff on branded pharmaceutical imports effective October 1 unless companies are actively building manufacturing plants in the U.S., defined as at groundbreaking...
Innovations in Radiation Oncology Presented at ASTRO 2025 Conference
Leading academic cancer centers showcased groundbreaking radiation therapy advances at the 2025 ASTRO Annual Meeting. UCLA Health highlighted personalized radiation using genomic adjusted...
AI and Machine Learning Boost Innovations in Medical Diagnostics and Therapeutics
Artificial intelligence (AI) and machine learning technologies continue to transform biotech and healthcare. Novel AI models enhance accuracy in lung lesion bronchoscopy and medical diagnosis...
Breakthrough Gene Editing Tools Enable Megabase-Scale DNA Rearrangements
Researchers at the Arc Institute developed programmable bridge recombinases, RNA-guided enzymes capable of executing large-scale genomic rearrangements in human cells. This technology enables...
Novel Cancer Immunotherapy Targets Glycan Antigens to Spare Healthy Tissue
Scientists at UC Irvine engineered glycan-dependent T cell recruiter (GlyTR) compounds that selectively bind tumor-associated carbohydrate antigens, activating T cells to kill diverse cancer cells...
NIH Launches $87 Million Standardized Organoid Modeling Center
The National Institutes of Health announced funding for the Standardized Organoid Modeling Center (SOMC) to accelerate development and reproducibility in organoid research, allocating $87 million...
Discovery of Candida albicans Toxin Regulation Enables Persistent Oral Colonization
A team of researchers revealed that Candida albicans utilizes finely balanced production of the toxin candidalysin to establish long-term colonization in the oral mucosa while evading immune...
FDA Clears Crinetics’ Oral Pill for First-Line Acromegaly Treatment
The U.S. Food and Drug Administration has approved Crinetics Pharmaceuticals’ Palsonify (paltusotine), marking the company's first authorized product. This once-daily oral therapy targets...
Eli Lilly’s Oral SERD Inluriyo Approved for ESR1-Mutated Breast Cancer
Eli Lilly received FDA approval for Imlunestrant (Inluriyo), an oral selective estrogen receptor degrader, to treat adults with advanced or metastatic estrogen receptor-positive, HER2-negative...
Trump Administration Imposes 100% Tariffs on Imported Branded Pharmaceuticals
President Donald Trump announced a 100% tariff on imported branded pharmaceutical products effective October 1, 2025, with carve-outs for generic drugs and exemptions for companies building...
ARPA-H Launches Nine-Figure Programs to Expand Personalized Gene Editing Therapies
The Advanced Research Projects Agency for Health (ARPA-H) unveiled two multi-million-dollar initiatives, THRIVE and GIVE, aimed at accelerating development and manufacturing of custom gene editing...
Bridge Recombinase Technology Enables Megabase-Scale DNA Rearrangements in Human Cells
Researchers at the Arc Institute have engineered a novel, RNA-guided bridge recombinase platform that enables programmable large-scale genomic DNA rearrangements, including insertions, deletions,...
UCI Develops Pan-Cancer Immunotherapy Targeting Glycan Antigens With Reduced Toxicity
Scientists at the University of California, Irvine, introduced glycan-dependent T cell recruiter (GlyTR) compounds that selectively bind tumor-associated carbohydrate antigens to trigger potent...